Cardiff Oncology (CRDF) Upgraded to Buy: Heres What You Should Know
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
2,635€
2,33%
Echtzeit-Aktienkurs Cardiff Oncology Inc.
Bid:
Ask:
Nachrichten zur Cardiff Oncology Inc. Aktie
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
…
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
…
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do…
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
…
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
…
Cardiff Oncology Inc. (CRDF): Studiendaten, Kapitalerhöhung und Insiderkäufe!
Cardiff Oncology Inc. (CRDF) ist ein Biotech mit Fokus auf die Behandlung von Krebserkrankungen. PLK1 (Polo-like kinase 1) ist ein…
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
…
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy…
Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer
…
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
…
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
…
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
…
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
…
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
…
Cardiff Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do…